Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

Immunotherapy offers deep and durable disease control to some patients, but many tumors do not respond to treatment with single-agent immune checkpoint inhibitors (ICIs). One strategy to enhance responses to immunotherapy is via combinations with signal transduction inhibitors, such as antiangiogeni...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkins, Michael B, Ascierto, Paolo A, Feltquate, David, Gulley, James L, Johnson, Douglas B, Khushalani, Nikhil I, Sosman, Jeffrey, Yap, Timonthy A, Kluger, Harriet, Sullivan, Ryan J, Tawbi, Hussein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Position Article and Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016252/
https://www.ncbi.nlm.nih.gov/pubmed/36918225
http://dx.doi.org/10.1136/jitc-2022-005923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10016252/
https://www.ncbi.nlm.nih.gov/pubmed/36918225
http://dx.doi.org/10.1136/jitc-2022-005923

Ejemplares similares